Patents by Inventor CLIFFORD MILLS CASSIDY

CLIFFORD MILLS CASSIDY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230389854
    Abstract: A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to one or more neurological conditions.
    Type: Application
    Filed: May 15, 2023
    Publication date: December 7, 2023
    Inventors: Samuel CLARK, Clifford Mills CASSIDY, Pedro ROSA-NETO, Kenneth WENGLER, Guillermo HORGA HERNANDEZ
  • Publication number: 20230200716
    Abstract: The subject matter disclosed herein relates to a method for determining dopamine function in a subject, the method comprising acquiring one or more neuromelanin-Magnetic Resonance Imaging (NM-MRI) scans of the subject's dopamine-associated brain region of interest.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 29, 2023
    Inventors: Guillermo Horga HERNANDEZ, Clifford Mills CASSIDY, Kenneth WENGLER
  • Publication number: 20220273184
    Abstract: A neuromelanin sensitive magnetic resonance imaging (“MRI”) technique, method and computer-accessible medium for measuring the extent of, providing a diagnosis of, monitoring the treatment of, assessing novel treatments for, or determining a prognosis related to Parkinson's disease.
    Type: Application
    Filed: August 17, 2020
    Publication date: September 1, 2022
    Inventors: Samuel CLARK, Guillermo HORGA HERNANDEZ, Clifford Mills CASSIDY, Kenneth WENGLER
  • Publication number: 20210228144
    Abstract: An exemplary system, method and computer-accessible medium for determining a dopamine function of a patient(s) can include, for example, receiving imaging information of a brain of the patient(s), determining a Neuromelanin (NM) concentration of the patient(s) based on the imaging information, and determining the dopamine function based on the NM concentration. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s). The topographical pattern(s) can include a pattern(s) of cell loss in the SN. The NM concentration can be based on a NM loss in the brain of the patient(s).
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Inventors: GUILLERMO HORGA HERNANDEZ, CLIFFORD MILLS CASSIDY